Related Experiment Video
Updated: Aug 17, 2026

Quantitative Detection of DNA-Protein Crosslinks and Their Post-Translational Modifications
Published on: April 21, 2023
SCAN1 mutant Tdp1 accumulates the enzyme--DNA intermediate and causes camptothecin hypersensitivity
Heidrun Interthal1, Hong Jing Chen, Thomas E Kehl-Fie
1Department of Microbiology, School of Medicine, University of Washington, Seattle, WA 98195-7242, USA.
Abstract:
Tyrosyl-DNA phosphodiesterase (Tdp1) catalyzes the hydrolysis of the tyrosyl-3' phosphate linkage found in topoisomerase I-DNA covalent complexes. The inherited disorder, spinocerebellar ataxia with axonal neuropathy (SCAN1), is caused by a H493R mutation in Tdp1. Contrary to earlier proposals that this disease results from a loss-of-function mutation, we show here that this mutation reduces enzyme activity approximately 25-fold and importantly causes the accumulation of the Tdp1-DNA covalent reaction intermediate. Thus, the attempted repair of topoisomerase I-DNA complexes by Tdp1 unexpectedly generates a new protein-DNA complex with an apparent half-life of approximately 13 min that, in addition to the unrepaired topoisomerase I-DNA complex, may interfere with transcription and replication in human cells and contribute to the SCAN1 phenotype. The analysis of Tdp1 mutant cell lines derived from SCAN1 patients reveals that they are hypersensitive to the topoisomerase I-specific anticancer drug camptothecin (CPT), implicating Tdp1 in the repair of CPT-induced topoisomerase I damage in human cells. This finding suggests that inhibitors of Tdp1 could act synergistically with CPT in anticancer therapy.
Insights
The spinocerebellar ataxia with axonal neuropathy (SCAN1) mutation impairs tyrosyl-DNA phosphodiesterase (Tdp1) activity, causing intermediate buildup. This Tdp1-DNA complex may drive SCAN1 pathology and suggests Tdp1 inhibitors could enhance cancer therapy.
Area of Science:
- Biochemistry
- Genetics
- Neuroscience
Background:
- Tyrosyl-DNA phosphodiesterase (Tdp1) resolves topoisomerase I-DNA adducts.
- Spinocerebellar ataxia with axonal neuropathy (SCAN1) is linked to Tdp1 mutations.
- Previous studies suggested SCAN1 results from Tdp1 loss-of-function.
Purpose of the Study:
- Investigate the functional impact of the SCAN1-associated H493R Tdp1 mutation.
- Determine the role of Tdp1 in repairing topoisomerase I-induced DNA damage.
- Explore therapeutic strategies involving Tdp1 inhibition.
Main Methods:
- Enzyme activity assays to quantify Tdp1 catalytic function.
- Analysis of Tdp1-DNA covalent intermediate accumulation.
- Cellular assays assessing sensitivity to topoisomerase I inhibitors.
Main Results:
- The H493R mutation reduces Tdp1 activity by approximately 25-fold.
- The mutation leads to the accumulation of a Tdp1-DNA covalent intermediate.
- SCAN1 patient-derived Tdp1 mutant cells exhibit hypersensitivity to camptothecin (CPT).
Conclusions:
- The SCAN1 mutation causes a partial loss-of-function and generates a persistent Tdp1-DNA intermediate.
- This intermediate, alongside unrepaired topoisomerase I-DNA complexes, may contribute to SCAN1 pathogenesis.
- Tdp1 plays a crucial role in repairing camptothecin-induced DNA damage, suggesting Tdp1 inhibitors could potentiate anticancer treatments.
Related Concept Videos
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Abnormal Proliferation
Spontaneous and Induced Mutations
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Inhibition of Cdk Activity
